 The FDA has granted Fast Track designation to NuCana plcs NASDAQ: NCNA Acelarin NUC-1031 for the first-line treatment of patients with advanced biliary tract cancer. The Company recently announced the enrollment of 418 evaluable patients in the Phase 3 study, which is expected to enable the first interim analysis in 1H of 2022. 